Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03014050 · ClinicalTrials.gov registry record · Early Phase 1
Bio Electro Stimulation Therapy for Parkinson's Disease
A Early Phase 1 study, sponsored by Boston University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT03014050: Completed Early Phase 1 study, sponsored by Boston University.
NCT03014050 is a Early Phase 1 study that has completed, run by Boston University. The registered enrollment target is 21 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03014050, a Early Phase 1 study, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction and non-motor symptoms. Here, the investigators propose in a pilot device feasibility trial to examine whether "Bio Electro Stimulation Therapy" (B.E.S.T.) with a small, non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hand can ameliorate some of the symptoms of PD.
Primary Outcome
Assessment of physical activity with body-worn sensor
Interventions
- DEVICE e-Tapper TT-R1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-09-22 |
| Est. Completion | 2019-06-01 |
| Phase | Early Phase 1 |
What the finished NCT03014050 record still lists
NCT03014050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which e-Tapper TT-R1 is the first listed.
NCT03014050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03014050 about?
NCT03014050 is a clinical study titled "Bio Electro Stimulation Therapy for Parkinson's Disease". Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction and non-motor symptoms. Here, the investigators propose in a pilot device feasibility trial to examine whether "Bio Electro Stimulation Therapy" (B.E.S.T.) with a small, non-invasive, handheld electronic devi...
What is the current status of trial NCT03014050?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2017-09-22. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT03014050?
The interventions under investigation include: e-Tapper TT-R1 (DEVICE).
Who is sponsoring clinical trial NCT03014050?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03014050's enrollment target sits among peer trials
21 1130th of 2000 higher than 845 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI